55121-08-9

Usage

Uses

Used in Polyurethane Industry:
4-Chlorophenethyl isocyanate, 97% is used as a key chemical intermediate for the synthesis of polyurethane foams, which are versatile materials with applications in furniture, bedding, automotive, and construction industries. Its reactivity allows for the production of high-quality foams with desired properties.
Used in Adhesives Industry:
In the adhesives industry, 4-chlorophenethyl isocyanate, 97% is utilized as a reactive component in the formulation of various adhesives. Its ability to form strong bonds with different substrates makes it suitable for use in construction, woodworking, and packaging applications.
Used in Coatings Industry:
4-Chlorophenethyl isocyanate, 97% is employed in the development of high-performance coatings, such as automotive and industrial coatings. Its reactivity contributes to the formation of durable and weather-resistant coatings with excellent adhesion properties.
Used in Pharmaceutical Industry:
Although not explicitly mentioned in the provided materials, 4-chlorophenethyl isocyanate, 97% may also be used as a building block in the synthesis of pharmaceutical compounds due to its reactive nature and potential to form various chemical structures. Its use in this industry would be for the development of new drugs and therapeutic agents.

InChI:InChI=1/C9H8ClNO/c10-9-3-1-8(2-4-9)5-6-11-7-12/h1-4H,5-6H2

Upstream product

• 75-44-5 phosgene 
• 2492-83-3 2-(4-chlorophenyl)ethanamine hydrochloride 
• 156-41-2 4-chlorophenylethylamine 
• 503-38-8 trichloromethyl chloroformate 
• 167886-56-8 1-[2-(tert-butoxycarbonylamino)ethyl]4-chlorobenzene 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 860436-77-7 2,2,2-trichloro-N-[2-(2-chlorophenyl)ethyl]acetamide 

Downstream Products

• 65535-88-8 3,3-dimethyl-1,5-dioxa-9-aza-spiro[5.5]undecane-9-carboxylic acid 4-chloro-phenethylamide 
• 22245-95-0 7-chloro-1,2,3,4-tetrahydroisoquinolin-1-one 
• 1002100-69-7 C₁₉H₂₀ClN₃O₂ 
• 1438289-08-7 1-(4-chlorophenethyl)-3-(4-methylcyclohexyl)pyrimidine-2,4,6(1H,3H,5H)-trione 
• 1438288-29-9 1-(4-chlorophenethyl)-3-(4-methylcyclohexyl)pyrimidine-2,4,6(1H,3H,5H)-trione 
• 1017125-41-5 C₁₆H₂₃ClN₂O 
• 1438288-33-5 (S)-1-(4-chlorophenethyl)-3-(1-cyclohexylethyl)pyrimidine-2,4,6(1H,3H,5H)-trione 
• 1438288-35-7 (R)-1-(4-chlorophenethyl)-3-(1-cyclohexylethyl)pyrimidine-2,4,6(1H,3H,5H)-trione 
• 1438288-39-1 1-((1R,2S,4S)-bicyclo[2.2.1]heptan-2-yl)-3-(4-chlorophenethyl)pyrimidine-2,4,6(1H,3H,5H)-trione 

Relevant academic research and scientific papers

Synthesis of 3,4-dihydroisoquinolin-1-ones from N-Boc-(β-Arylethyl) carbamates via isocyanate intermediates

Mild reaction conditions for the regioselective synthesis of isoquinolin-1-ones and related fused-ring heterocycles from N-Boc-protected (β-arylethyl)carbamates are described. The reactions involved the use of Tf2O and 2-chloropyridine and isocyanates are likely to be key intermediates. The method was extended to substrates bearing less nucleophilic aryl moieties by using Lewis acid additives, such as BF3· Et2O, to enhance the Friedel-Crafts-type cyclization of the isocyanate intermediates. This method allowed the synthesis of various substituted isoquinolin-1-ones, β-carbolines, thiophene-fused ring systems and tetrahydrobenzoazepin-1-ones in good yields and with high regioselectivities. Copyright

Anticonvulsant properties of histamine H3 receptor ligands belonging to N-substituted carbamates of imidazopropanol

Ligands targeting central histamine H3 receptors (H 3Rs) for epilepsy might be a promising therapeutic approach. Therefore, the previously described and structurally strongly related imidazole-based derivatives belonging to carbamate

New N-arachidonoylserotonin analogues with potential "dual" mechanism of action against pain

N-Arachidonoylserotonin (AA-5-HT, 1a) is an inhibitor of fatty acid amide hydrolase (FAAH) that acts also as an antagonist of transient receptor potential vanilloid-type 1 (TRPV1) channels and is analgesic in rodents. We modified the chemical structure of 1a with the aim of developing "hybrid" FAAH/TRPV1 blockers more potent than the parent compound or obtaining analogues with single activity at either of the two targets to study the mechanism of the analgesic action of 1a. Thirty-eight AA-5-HT analogues, containing a serotonin "head" bound to a variety of lipophilic moieties via amide, urea, or carbamate functionalities, were synthesized. Unlike 1a, most of the new compounds possessed activity at only one of the two considered targets. The amides 1b and 1c of α- and γ-linolenic acid, however, showed "hybrid" activity similar to 1a. The carbamate 3f (OMDM106), although unable to antagonize TRPV1 receptors, was the most potent FAAH inhibitor in this study (IC50 = 0.5 μM). Compounds 3f and 1m (OMDM129), which exhibited activity at only FAAH or TRPV1, respectively, were 10-fold less potent than 1a at preventing formalin-induced hyperalgesia in mice.

Bronchorelaxing agents based on indol- and isoquinoline derivatives

A compound of formula (I) and its acid addition salts, wherein R1-FIj are H, lower (CrC6) alkyl; halogen; NR5R6, wherein R5, R6 are H, lower alkyl, C2-C6 acyl, SO2R7, wherein R7 is lower alkyl, CF3, aryl, substituted aryl; CN; COR8, wherein R8 is H, OH, lower alkyl, lower alkoxy; SO2R9, wherein R9 is OR10, wherein R10 is H, lower alkyl or NRnR12, wherein R11 and R12 is H or lower alkyl; ORi3, wherein R13 is H, lower alkyl, C2-C6 acyl, C1-C8 carboxy, C1-C8 carbamoyl; X is O or S; A is H, lower alkyl; B is C1-C18 alkyl optionally substituted; M is zero or 1; with the proviso that no more than three of R1-R4 are H, for treating and preventing bronchoconstructive pulmonary disease.

Unexpected enhancement of thrombin inhibitor potency with o-aminoalkylbenzylamides in the P1 position

Thrombin inhibitors incorporating o-aminoalkylbenzylamides in the P1 position were designed, synthesized and found to have enhanced potency and selectivity in several different structural classes. X-ray crystallographic analysis of compound 24 bound in the α-thrombin-hirugen complex provides an explanation for these unanticipated results.